Jazz Pharmaceuticals plc (JAZZ) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	$6.18	$5.71	-7.6%	—	$1.2B	—
Q1 26	$4.66	$6.34	+36.1%	—	$1.1B	—
Q4 25	$6.51	$6.64	+2.0%	—	$1.2B	—
Q3 25	$5.85	$8.13	+39.0%	—	$1.1B	—
Q2 25	-$6.25	-$8.25	-32.0%	—	$1B	—
Q1 25	$4.66	$1.68	-63.9%	—	$897.8M	—
Q4 24	$5.81	$6.6	+13.6%	—	$1.1B	—
Q3 24	$5.5	$6.61	+20.2%	—	$1.1B	—
Q2 24	$4.78	$5.3	+10.9%	—	$1B	—
Q1 24	$4.18	$2.68	-35.9%	—	$902M	—
Q4 23	$5.18	$5.02	-3.1%	—	$1B	—
Q3 23	$4.93	$4.84	-1.8%	—	$972.1M	—
Q2 23	$4.43	$4.51	+1.8%	—	$957.3M	—
Q1 23	$4.24	$3.95	-6.8%	—	$892.8M	—
Q4 22	$0.32	-$0.07	-121.9%	—	$972.1M	—
Q3 22	$4.66	$5.17	+10.9%	—	$940.7M	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	-$5.84	—	—	$4.3B	—
FY24	—	$9.06	—	—	$4.1B	—
FY23	—	$6.55	—	—	$3.8B	—
FY22	—	-$3.58	—	—	$3.7B

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$1.5B	$1.6B	$1.9B	$2.2B	$2.4B	$3.1B	$3.7B	$3.8B	$4.1B	$4.3B
YoY change	+12.3%	+8.79%	+16.8%	+14.3%	+9.34%	+30.9%	+18.3%	+4.78%	+6.12%	+4.88%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	1.5B	1.6B	1.9B	2.2B	2.4B	3.1B	3.7B	3.8B	4.1B	4.3B
Cost of revenue	105.4M	110.2M	121.5M	127.9M	148.9M	440.8M	540.5M	435.6M	445.7M	503.3M
Gross profit	1.4B	1.5B	1.8B	2B	2.2B	2.7B	3.1B	3.4B	3.6B	3.8B
Gross margin	92.9%	93.2%	93.6%	94.1%	93.7%	85.8%	85.2%	88.6%	89%	88.2%
Research & development	162.3M	198.4M	226.6M	299.7M	335.4M	505.7M	590.5M	849.7M	884M	782.7M
Selling, general & administrative	502.9M	544.2M	683.5M	736.9M	854.2M	1.5B	1.4B	1.3B	1.4B	1.8B
Operating expenses	665.2M	742.6M	910.1M	1B	1.2B	2B	2B	2.2B	2.3B	2.6B
Operating income	615.4M	613.8M	657.7M	642.3M	765.5M	170.3M	512.3M	597.6M	726.6M	517.6M
Operating margin	41.4%	37.9%	34.8%	29.7%	32.4%	5.5%	14%	15.6%	17.9%	12.1%
Non-operating income, net	-21M	-95M	-49.8M	-115.8M	-390.7M	-4.3M	-596.8M	-10.2M	-18.2M	-950.4M
Pretax income	532.4M	441.1M	529.5M	454.3M	275.1M	-112.8M	-372.8M	297.9M	470.4M	-627.9M
Income tax	135.2M	-47.7M	80.2M	-73.2M	33.5M	216.1M	-158.6M	-119.9M	-91.4M	-272.4M
Net income	396.8M	487.8M	447.1M	523.4M	238.6M	-329.7M	-224.1M	414.8M	560.1M	-356.1M
Net margin	26.7%	30.1%	23.6%	24.2%	10.1%	-10.7%	-6.12%	10.8%	13.8%	-8.35%
EBITDA	729.2M	779M	874.5M	1B	1B	722.8M	1.1B	1.2B	1.4B	1.2B
EPS	6.56	8.13	7.45	9.22	4.28	-5.52	-3.58	6.55	9.06	-5.84
Diluted EPS	6.41	7.96	7.3	9.09	4.22	-5.52	-3.58	6.1	8.65	-5.84

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	972.1M	1B	902M	1B	1.1B	1.1B	897.8M	1B	1.1B	1.2B	1.1B	1.2B
Cost of revenue	102.2M	107.2M	95.5M	109.9M	111.6M	128.7M	104.6M	116.3M	128.9M	153.5M	134.1M	116.4M
Gross profit	870M	904.7M	806.5M	913.9M	943.4M	959.5M	793.2M	929.4M	997.2M	1B	934.8M	1.1B
Gross margin	89.5%	89.4%	89.4%	89.3%	89.4%	88.2%	88.3%	88.9%	88.6%	87.2%	87.5%	90.4%
Research & development	234.4M	216.6M	222.8M	220.7M	199.9M	240.5M	180.7M	190M	198.2M	213.9M	196M	207.5M
Selling, general & administrative	308.3M	396M	351.7M	338.5M	325.8M	369.3M	514M	358.4M	530.6M	406.2M	352.7M	389.2M
Operating expenses	542.7M	612.6M	574.6M	559.3M	525.7M	609.8M	694.7M	548.4M	728.9M	620.1M	425.9M	596.7M
Operating income	172.4M	140.5M	76.2M	199.4M	260.2M	190.8M	-55.9M	219M	100M	254.5M	336.6M	325.2M
Operating margin	17.7%	13.9%	8.45%	19.5%	24.7%	17.5%	-6.23%	20.9%	8.88%	21.2%	31.5%	26.9%
Non-operating income, net	-1.4M	-8.6M	-11.7M	507K	-701K	-6.3M	-213K	-907.2M	-42.4M	-658K	2.5M	-77.1M
Pretax income	99.5M	61.5M	-1.6M	137.9M	200.8M	133.2M	-109.8M	-735.6M	9M	208.5M	299.2M	211M
Income tax	-47.2M	-33.1M	11.7M	-30.7M	-14.5M	-57.9M	-17.8M	-17.2M	-242.4M	5M	6.1M	18.1M
Net income	146.8M	94.2M	-14.6M	168.6M	215.1M	191.1M	-92.5M	-718.5M	251.4M	203.5M	293.1M	192.8M
Net margin	15.1%	9.3%	-1.62%	16.5%	20.4%	17.6%	-10.3%	-68.7%	22.3%	17%	27.4%	16%
EBITDA	334.9M	299.7M	239.6M	362.5M	425.4M	359.2M	109M	393.1M	278.3M	433.7M	518M	504.3M
EPS	2.33	1.5	-0.23	2.68	3.5	3.16	-1.52	-11.7	4.14	3.33	4.73	3.05
Diluted EPS	2.14	1.42	-0.23	2.49	3.42	3.11	-1.52	-11.7	4.08	3.21	4.43	2.78

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	6.6B	8.1B	7.4B	8.5B	9.2B	7.6B	10B	7.8B	7.6B	10.4B	15.5B
Enterprise value	8.2B	9.1B	8.2B	9.2B	9.3B	13.2B	14.9B	12B	10.8B	13.3B	17.7B
Shares outstanding	60.5M	60M	60M	56.7M	55.7M	59.7M	62.5M	63.3M	61.8M	61M	61M

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	16.6	16.6	16.6	16.2	38.5	—	—	18.8	13.6	—	16.3
P/S	4.43	4.99	3.93	3.92	3.89	2.46	2.72	2.03	1.87	2.43	3.36
P/B	3.51	2.98	2.7	2.72	2.51	1.92	3.23	2.08	1.86	2.4	3.21
EV/EBITDA	11.2	11.6	9.38	9.05	8.92	18.2	13	9.67	7.78	11	9.16
EV/Sales	5.51	5.6	4.34	4.24	3.94	4.26	4.07	3.12	2.65	3.13	3.84
Earnings yield	6.02%	6.04%	6.01%	6.18%	2.59%	—	—	5.33%	7.36%	—	6.14%
FCF yield	6.2%	7.17%	8.98%	7.01%	5.66%	9.64%	7.77%	13.5%	17.7%	11.1%	9.24%
PEG	—	—	—	—	—	—	—	—	—	—	-0.13

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	92.9%	93.2%	93.6%	94.1%	93.7%	85.8%	85.2%	88.6%	89%	88.2%	90.4%
Operating margin	41.4%	37.9%	34.8%	29.7%	32.4%	5.5%	14%	15.6%	17.9%	12.1%	26.9%
Net margin	26.7%	30.1%	23.6%	24.2%	10.1%	-10.7%	-6.12%	10.8%	13.8%	-8.35%	20.4%
ROE	21.1%	18%	16.2%	16.8%	6.52%	-8.31%	-7.26%	11.1%	13.7%	-8.25%	22.1%
ROA	8.27%	9.52%	8.59%	9.45%	3.65%	-2.68%	-2.07%	3.64%	4.66%	-3.05%	6.86%
ROIC	13.2%	16.6%	15.8%	16.9%	17.8%	1.79%	6.39%	7.56%	10%	7.09%	14.5%
Return on tangible assets	-13.2%	-17.9%	-21.1%	-44.2%	104.1%	5.82%	5.41%	-14.1%	-60.1%	41.5%	-162.8%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	2.91	3.29	3.57	4.47	4.34	3.23	2.79	2.24	4.46	1.86	1.78
Quick ratio	2.77	3.15	3.42	4.26	4.2	1.9	2.03	1.85	3.99	1.67	1.58
Debt / equity	1.08	0.58	0.58	0.57	0.61	1.55	1.88	1.55	1.51	1.26	0.92
Debt / assets	0.42	0.31	0.31	0.32	0.34	0.5	0.54	0.51	0.51	0.47	0.4
Net debt / EBITDA	2.2	1.26	0.88	0.69	0.11	7.69	4.32	3.37	2.29	2.46	1.27
Interest coverage	9.6	6.67	7.74	7.29	3.76	0.6	-0.29	2.03	2.98	-2.22	5.26
Effective tax rate	25.4%	0%	15.1%	0%	12.2%	0%	0%	0%	0%	0%	0%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	24.6	27	31.5	38.1	42.4	51.8	58.5	60.6	65.8	70	74.6
EPS (basic)	6.56	8.13	7.45	9.22	4.28	-5.52	-3.58	6.55	9.06	-5.84	-5.84
EPS (diluted)	6.41	7.96	7.3	9.09	4.22	-5.52	-3.58	6.1	8.65	-5.84	14.6
Book value per share	31	45.2	46	54.8	65.7	66.4	49.3	59	66.2	70.8	74.1
FCF per share	6.76	9.65	11.1	10.5	9.34	12.3	12.4	16.6	21.8	18.8	18.9
Cash per share	7.04	10	13.7	19	38.3	9.91	14.1	25.7	48.4	40	33.9
Capex per share	0.16	0.48	0.34	0.71	0.27	0.46	0.46	0.38	0.62	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	0.65%	1.79%	1.08%	1.86%	0.63%	0.89%	0.79%	0.62%	0.94%	—	—
Capex / operating cash flow	1.64%	4.09%	2.94%	5.07%	2%	3.86%	3.28%	2.09%	2.96%	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—	0%

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$972.1M	$1B	$902M	$1B	$1.1B	$1.1B	$897.8M	$1B	$1.1B	$1.2B	$1.1B	$1.2B
YoY change	+3.35%	+4.1%	+1.03%	+6.95%	+8.52%	+7.53%	-0.46%	+2.14%	+6.74%	+10.1%	+19.1%	+15.5%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	426M	601M	824.6M	1.1B	2.1B	591.4M	881.5M	1.6B	3B	2.4B
Receivables	234.2M	224.1M	263.8M	356M	396.5M	563.4M	651.5M	705.8M	716.8M	830.7M
Inventory	34.1M	43.2M	53M	78.6M	95.4M	1.1B	714.1M	597M	480.4M	417M
Total current assets	748.1M	968.3M	1.2B	1.6B	2.8B	2.6B	2.6B	3.4B	4.6B	4.2B
Property, plant & equipment	107.5M	170.1M	226.2M	270.9M	257.1M	343.4M	301.4M	235M	227M	258.7M
Goodwill & intangibles	7.8B	7.9B	7.3B	6.7B	6.3B	18B	15B	14.3B	12.9B	12.5B
Total assets	4.8B	5.1B	5.2B	5.5B	6.5B	12.3B	10.8B	11.4B	12B	11.7B
Accounts payable	22.4M	24.4M	40.6M	45.7M	26.9M	100.3M	90.8M	102.8M	77.9M	122.1M
Short-term debt	36.1M	40.6M	33.4M	46.1M	260.8M	46.8M	46.9M	624.4M	45.8M	1B
Total current liabilities	257.4M	293.9M	345.5M	364.5M	653.7M	809.3M	933.2M	1.5B	1B	2.2B
Long-term debt	2B	1.5B	1.6B	1.7B	2B	6.1B	5.8B	5.2B	6.1B	4.4B
Total liabilities	2.9B	2.4B	2.4B	2.4B	2.9B	8.3B	7.7B	7.7B	7.9B	7.3B
Shareholders' equity	1.9B	2.7B	2.8B	3.1B	3.7B	4B	3.1B	3.7B	4.1B	4.3B
Total debt	2B	1.6B	1.6B	1.8B	2.2B	6.2B	5.8B	5.8B	6.2B	5.4B
Net debt	1.7B	1.2B	1.3B	1.1B	1.2B	5.6B	4.9B	4.3B	3.7B	4B

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	1.6B	1.6B	1.8B	2B	2.6B	3B	2.6B	1.7B	2B	2.4B	2.9B	2.2B
Receivables	627.8M	705.8M	707.1M	698M	723.6M	716.8M	653M	714M	764.4M	830.7M	836.3M	880.9M
Inventory	611.8M	597M	577.3M	542.6M	539.3M	480.4M	492.8M	505M	483.1M	417M	437.5M	443M
Total current assets	3.2B	3.4B	3.5B	3.7B	4.4B	4.6B	4.1B	3.4B	3.8B	4.2B	4.6B	4B
Property, plant & equipment	287.5M	235M	227.9M	242.4M	253.6M	227M	228.1M	248.1M	250.1M	258.7M	258.9M	264.1M
Goodwill & intangibles	14.2B	14.3B	13.9B	13.6B	13.9B	12.9B	13B	13.2B	12.8B	12.5B	12B	11.7B
Total assets	11.2B	11.4B	11.3B	11.4B	12.3B	12B	11.5B	10.9B	11.4B	11.7B	11.9B	11.1B
Accounts payable	109.8M	102.8M	81M	97.1M	85.4M	77.9M	95.9M	89.4M	152.2M	122.1M	100M	128.5M
Short-term debt	621.2M	624.4M	623.7M	622.9M	50.1M	45.8M	44.4M	1B	1B	1B	1B	1B
Total current liabilities	1.6B	1.5B	1.6B	1.6B	1B	1B	1.2B	2.1B	2.3B	2.2B	2.2B	2.2B
Long-term debt	5.2B	5.2B	5.2B	5.2B	6.2B	6.1B	5.4B	4.4B	4.4B	4.4B	4.4B	3.4B
Total liabilities	7.7B	7.7B	7.6B	7.6B	8.1B	7.9B	7.4B	7.2B	7.4B	7.3B	7.3B	6.3B
Shareholders' equity	3.5B	3.7B	3.7B	3.8B	4.2B	4.1B	4.2B	3.7B	4B	4.3B	4.5B	4.8B
Total debt	5.8B	5.8B	5.8B	5.8B	6.2B	6.2B	5.4B	5.4B	5.4B	5.4B	5.4B	4.4B
Net debt	4.5B	4.3B	4.3B	4.4B	4B	3.7B	3.6B	4.2B	4.1B	4B	3.6B	2.8B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	396.8M	487.8M	447.1M	523.4M	238.6M	-329.7M	-224.1M	414.8M	560.1M	-356.1M
Depreciation & amortization	113.8M	165.2M	216.7M	370.2M	278.3M	552.5M	629.5M	638.7M	660.1M	696.3M
Stock-based compensation	98.8M	106.9M	102.4M	110.6M	121M	189M	222M	226.8M	248M	291.1M
Change in working capital	-20.1M	43.9M	-37.1M	-133M	-79.9M	-91.5M	-190.2M	-80.2M	-158.7M	-124.5M
Operating cash flow	590.2M	707.5M	691.7M	790.9M	748.6M	715.3M	886M	1.1B	1.3B	1.4B
Capital expenditure	-9.7M	-28.9M	-20.4M	-40.1M	-15M	-27.6M	-29M	-24M	-38.1M	—
Investing cash flow	-1.6B	-183.9M	-283.4M	-13.1M	-629.2M	-5.2B	22.9M	-144.1M	-498.2M	-1.3B
Dividends paid	—	—	—	—	—	—	—	—	—	—
Share repurchases	-278.3M	-98.8M	-523.7M	-301.4M	-146.5M	0	-54K	-269.8M	-311.4M	-125M
Financing cash flow	366.8M	-1.3B	-572.5M	-351.6M	-71.6M	3.8B	-627.5M	-351.7M	-131K	-981.2M
Net change in cash	-620.3M	-767.3M	-164.2M	426.2M	47.8M	-643.7M	281.4M	648.3M	787.8M	-925.6M
Free cash flow	409M	579.1M	667.4M	594.1M	520.4M	733M	773.8M	1B	1.3B	1.1B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	—	—	—	—	—	—	—	—	251.4M	203.5M	293.1M	192.8M
Depreciation & amortization	—	—	—	—	—	—	—	—	178.3M	179.2M	181.4M	179.1M
Stock-based compensation	—	—	—	—	—	—	—	—	88.1M	70.9M	74.5M	73.3M
Change in working capital	—	—	—	—	—	—	—	—	-1.5M	-58M	-93.5M	-70.1M
Operating cash flow	—	—	—	—	—	—	—	—	474.7M	362.5M	408.2M	415.7M
Capital expenditure	—	—	—	—	—	—	—	—	—	—	—	—
Investing cash flow	20M	250M	120M	80M	355M	290M	310M	470M	-240.1M	556.1M	142.8M	527.2M
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	—	—	—	—	-23K	0	—	—
Financing cash flow	—	—	—	—	—	—	—	—	-11.6M	-9.7M	-111.4M	-1B
Net change in cash	20M	250M	120M	80M	355M	290M	310M	470M	223M	908.9M	439.6M	-74.3M
Free cash flow	—	—	—	—	—	—	—	—	386.9M	292.3M	388.5M	243.4M

Jazz Pharmaceuticals plc Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement